APA

Molina J., Podsadecki T. J., Johnson M. A., Wilkin A., Domingo P., Myers R., Hairrell J. M., Rode R. A., King M. S. & Hanna G. J. (20080304). A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. : AIDS research and human retroviruses.

Chicago

Molina Jean-Michel, Podsadecki Thomas J, Johnson Margaret A, Wilkin Aimee, Domingo Pere, Myers Robert, Hairrell Jan M, Rode Richard A, King Martin S and Hanna George J. 20080304. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. : AIDS research and human retroviruses.

Harvard

Molina J., Podsadecki T. J., Johnson M. A., Wilkin A., Domingo P., Myers R., Hairrell J. M., Rode R. A., King M. S. and Hanna G. J. (20080304). A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. : AIDS research and human retroviruses.

MLA

Molina Jean-Michel, Podsadecki Thomas J, Johnson Margaret A, Wilkin Aimee, Domingo Pere, Myers Robert, Hairrell Jan M, Rode Richard A, King Martin S and Hanna George J. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. : AIDS research and human retroviruses. 20080304.